Association between calcineurin inhibitor treatment and peripheral nerve dysfunction in renal transplant recipients

American Journal of Transplantation

Volumn 13, Issue 9, 2013, Pages 2426-2432

  Arnold, R ^a   Pussell, B A ^b   Pianta, T J ^b,c   Lin, C S Y ^a   Kiernan, M C ^c   Krishnan, A V ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Calcineurin inhibitors; nerve excitability; neuropathy; renal transplant

Indexed keywords

CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID; RAPAMYCIN; TACROLIMUS;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HEMODIALYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDY; MALE; MONOTHERAPY; NERVE CELL MEMBRANE STEADY POTENTIAL; NERVE EXCITABILITY; NERVE FUNCTION; NEUROTOXICITY; PERIPHERAL NERVE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; TREATMENT DURATION;

CALCINEURIN INHIBITORS; NERVE EXCITABILITY; NEUROPATHY; RENAL TRANSPLANT;

ADULT; AGED; CALCINEURIN; CROSS-SECTIONAL STUDIES; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; TACROLIMUS;

EID: 84883451866     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12324     Document Type: Article

References (30)

1. Wijdicks EF., Neurotoxicity of immunosuppressive drugs. Liver Transplant 2001; 7: 937-942.
2. Bechstein WO., Neurotoxicity of calcineurin inhibitors: Impact and clinical management. Transpl Int 2000; 13: 313-326.
3. Veroux P, Veroux M, Puliatti C, et al. Tacrolimus-induced neurotoxicity in kidney transplant recipients. Transplant Proc 2002; 34: 3188-3190.
4. Tan TC, Robinson PJ., Mechanisms of calcineurin inhibitor-induced neurotoxicity. Transplant Rev 2006; 20: 49-60.
5. Moreno E, Gomez SR, Gonzalez I, et al. Neurologic complications in liver transplantation. Acta Neurol Scand 1993; 87: 25-31.
6. Krishnan AV, Goldstein D, Friedlander M, Kiernan MC., Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 2005; 32: 51-60.
7. Krishnan AV, Park SB, Huynh W, Lin CS, Henderson RD, Kiernan MC., Impaired energy-dependent processes underlie acute lead neuropathy. Muscle Nerve 2012; 46: 957-961.
8. Krishnan AV, Lin CS, Park SB, Kiernan MC., Axonal ion channels from bench to bedside: A translational neuroscience perspective. Prog Neurobiol 2009; 89: 288-313.
9. Krishnan AV, Phoon RK, Pussell BA, Charlesworth JA, Kiernan MC., Sensory nerve excitability and neuropathy in end stage kidney disease. J Neurol Neurosurg Psychiatry 2006; 77: 548-551.
10. Krishnan AV, Phoon RK, Pussell BA, Charlesworth JA, Bostock H, Kiernan MC., Altered motor nerve excitability in end-stage kidney disease. Brain 2005; 128: 2164-2174.
11. Laaksonen S, Metsarinne K, Voipio-Pulkki LM, Falck B., Neurophysiologic parameters and symptoms in chronic renal failure. Muscle Nerve 2002; 25: 884-890.
12. Cornblath DR, Chaudhry V, Carter K, et al. Total neuropathy score: Validation and reliability study. Neurology 1999; 53: 1660-1664.
13. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D., A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
14. Kiernan MC, Walters RJL, Andersen KV, Taube D, Murray NMF, Bostock H., Nerve excitability changes in chronic renal failure indicate membrane depolarization due to hyperkalaemia. Brain 2002; 125: 1366-1378.
15. Kiernan MC, Burke D, Andersen KV, Bostock H., Multiple measures of axonal excitability: A new approach in clinical testing. Muscle Nerve 2000; 23: 399-409.
16. Bostock H, Cikurel K, Burke D., Threshold tracking techniques in the study of human peripheral nerve. Muscle Nerve 1998; 21: 137-158.
17. Krishnan AV, Lin CS, Park SB, Kiernan MC., Assessment of nerve excitability in toxic and metabolic neuropathies. J Peripher Nerv Syst 2008; 13: 7-26.
18. Kiernan MC, Bostock H., Effects of membrane polarization and ischaemia on the excitability properties of human motor axons. Brain 2000; 123: 2542-2551.
19. Mogyoros I, Bostock H, Burke D., Mechanisms of paresthesias arising from healthy axons. Muscle Nerve 2000; 23: 310-320.
20. Krishnan AV, Lin CSY, Kiernan MC., Activity-dependent excitability changes suggest Na(+)/K(+) pump dysfunction in diabetic neuropathy. Brain 2008; 131: 1209-1216.
21. Krishnan AV, Lin CS, Kiernan MC., Excitability differences in lower-limb motor axons during and after ischemia. Muscle Nerve 2005; 31: 205-213.
22. Textor SC, Taler SJ, Canzanello VJ, Schwartz L, Augustine JE., Posttransplantation hypertension related to calcineurin inhibitors. Liver Transplant 2000; 6: 521-530.
23. Morales JM, Andres A, Rengel M, Rodicio JL., Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant 2001; 16 (Suppl 1): 121-124.
24. Textor SC, Canzanello VJ, Taler SJ, et al. Cyclosporine-induced hypertension after transplantation. Mayo Clin Proc 1994; 69: 1182-1193.
25. Joannides R, Etienne I, Iacob M, et al. Comparative effects of sirolimus and cyclosporin on conduit arteries endothelial function in kidney recipients. Transpl Int 2010; 23: 1135-1143.
26. Lea JP, Sands JM, McMahon SJ, Tumlin JA., Evidence that the inhibition of Na+/K(+)-ATPase activity by FK506 involves calcineurin. Kidney Int 1994; 46: 647-652.
27. Stys PK., General mechanisms of axonal damage and its prevention. J Neurol Sci 2005; 233: 3-13.
28. Forgacs B, Merhav HJ, Lappin J, Mieles L., Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation. Transplant Proc 2005; 37: 1912-1914.
29. Maramattom BV, Wijdicks EF., Sirolimus may not cause neurotoxicity in kidney and liver transplant recipients. Neurology 2004; 63: 1958-1959.
30. Sayin R, Soyoral YU, Erkoc R., Polyneuropathy due to cyclosporine A in patients with renal transplantation: A case report. Ren Fail 2011; 33: 528-530.